Labcorp Launches Weight Loss Management Testing Solutions

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C. , March 7, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services,

Addressing Challenges with Ulcerative Colitis Clinical Study Recruitment

We understand the significant challenges sponsors face with patient recruitment in their ulcerative colitis (UC) clinical studies. While the prevalence of UC is relatively high (~0.2% in North America, Oceania and much of Europe – and rising in urbanized/industrialized countries in Africa, Asia and Latin America1), recruitment rates into clinical studies are woefully low. Achieving a linear average recruitment rate of just 0.1 patients/site/month* is considered the standard (*calculated by dividing total patient accrual by number of sites by overall recruitment window [months]).

The role of B-cell cloning in the generation of antibody critical reagents: apoptosis-related antigen case study

B-cell cloning, a recent improvement over typical hybridoma technology, is becoming an industry standard tool for the reliable and reproducible production of monoclonal antibodies. Read on to find out how we have successfully utilized B-cell cloning to produce antibody critical reagents, for a recombinant protein, and to learn how this service offering can help you by supplying antibody critical reagents specific to your clinical development needs.1,2

Non-GLP sample analysis for ocular biodistribution studies

Traditional bioanalytical service providers are geared toward analyzing large sets of samples under various regulatory guidelines, such as large nonclinical and clinical studies, which are heavily regulated. This puts a heavy burden on these service providers, creating long lead times, resource constraints and lack of flexibility. Currently, many bioanalytical laboratories report lead times of six to nine months to begin development work. These limited bioanalytical options are causing extensive delays in overall drug development affecting the finances of sponsors.

New OECD TG 497: Interpretation and application of defined approaches for skin sensitization assessment

The advent of requiring multiple non-animal in vitro alternatives for skin sensitization assessments has prompted the Organisation for Economic Co-operation and Development (OECD) to publish new guidance to outline the approaches for data interpretation from multiple non-animal test methods. When used together in specific combinations, these methods will aid with skin sensitization hazard identification and, potentially, potency characterization. A detailed scientific understanding of how best to apply these methods and/or test strategies is needed to address the requirements of regulators for different test chemicals (molecules, chemicals, substances, etc.). This blog will provide an overview of these defined approaches (DAs).

An introduction to dendritic cell biology and analysis using syngeneic immuno-oncology models

Productive immunotherapy driven anti-tumor responses rely on the activation of T cells that target tumor-associated antigens (TAA). The dendritic cell (DC) plays an essential role in the activation of T cell antigen-specific responses, which occur naturally in the context of infection. However, this same process supports tumor-immune surveillance as well as active anti-tumor responses.

Why is cytotoxicity testing critical in medical device development?

Cytotoxicity testing is a critical step in medical device evaluation, but it comes with many challenges. Factors like device composition, sample preparation and contamination can impact biocompatibility results. With so much riding on accurate safety data, it is essential to understand the challenges and considerations for skillful navigation.

The Heart of the Matter: Early Risk Identification & Prevention are Key to Reducing Cardiovascular Disease

Heart disease costs employers and individuals nearly $1 billion a day in medical costs and lost productivity. According to some studies, approximately 800,000 Americans die each year from heart disease, stroke and other cardiovascular diseases. That accounts for one in every three deaths in the United States, and one of every six dollars employers spend on healthcare. And, it’s worse for women. Heart disease is the leading cause of death among women, and one of the most preventable.  How can employers help employees prepare for and avoid heart disease? Focusing on digital health, prevention and identifying risk early are key strategies to improving cardiovascular health outcomes. Watch this webinar to hear speakers share: The impact cardiovascular disease can have on workforce health Why women are most at risk  How early detection and prevention-focused care can fuel health programs and drive a healthier, more resilient and cost-effective workforce